In a Phase I study, ME-344, an isoflavone-derived complex I mitochondrial inhibitor, is being evaluated in early stage HER2-negative breast cancer patients in combination with bevacizumab, an anti-vascular endothelial growth factors A (VEGF-A) inhibitor, assessing whether combination of ME-344 and bevacizumab can offset the metabolic changes that occur with anti-VEGF treatment (NCT02806817). Here, VEGFA is linked to breast carcinoma.